What people are reporting about HCG on TRT and during PCT

You start testosterone replacement therapy and things improve in the ways you hoped — energy, mood, libido, the general sense that your body has remembered something it had quietly forgotten. Then, a few months in, you look down in the shower and notice your testicles are smaller. Nobody warned you. Or maybe they did, in one sentence buried in paperwork, and you didn't fully absorb what it meant until you were standing there.

Testicular atrophy on exogenous testosterone is not a side effect. It's a mechanism. When you introduce testosterone from outside the body, your pituitary reads the level, sees that circulating testosterone is adequate, and stops signaling the testes to produce their own. Specifically, it stops releasing luteinizing hormone — LH — which is the signal that tells the Leydig cells in the testes to synthesize testosterone and which also drives spermatogenesis in partnership with follicle-stimulating hormone. Absent LH, the testes become dormant. They atrophy. They shrink. This is entirely predictable, it happens to most men on TRT to some degree, and it is one of the central subjects in the communities around testosterone replacement therapy.

Human chorionic gonadotropin — HCG — is an LH analog. It binds to LH receptors with enough structural similarity to LH that the testes, which cannot distinguish between the two, respond as if the pituitary is still communicating. Leydig cells resume activity. Testicular volume is maintained or restored. Intratesticular testosterone — the testosterone produced inside the testes, distinct from what you're injecting — is preserved. And because spermatogenesis depends on intratesticular testosterone levels that are far higher than serum levels, HCG is the primary tool men use when they want to remain on TRT without sacrificing fertility.

HCG is FDA-approved for specific fertility indications — stimulating ovulation in women, treating certain forms of hypogonadism, and prepubertal cryptorchidism in boys. Its use as an adjunct to TRT in men is off-label. What follows is what the communities say about how that off-label use plays out in practice.

The testicular size conversation on r/Testosterone and similar forums has a particular texture: it's one of the few places online where men talk about this change openly, with a mix of pragmatism and something more personal. The reports on HCG follow a consistent pattern. Men who add HCG to their TRT protocol — typically at 250 to 500 IU injected two to three times per week, which is the dominant dosing pattern across these forums — describe noticing testicular volume beginning to return within a few weeks. Full restoration, where it occurs, tends to take months rather than weeks. Some men report that what returns is not quite what was there before TRT, particularly if they had been on testosterone for years before adding HCG. The longer the testes have been dormant, the more variable the restoration. This is a frequently repeated observation, and it aligns with what the biology would suggest: prolonged absence of LH signaling appears to reduce the responsiveness of Leydig cells over time.

Libido is the second major theme in these discussions, and it's more complicated than the testicular size conversation. Many men report that adding HCG improves libido beyond what TRT alone was providing — they describe a quality difference, a kind of drive or urgency that was absent even when serum testosterone was optimized. The hypothesis, repeated throughout these communities and referenced in the literature they cite, is that intratesticular testosterone and the local hormonal environment of the testes contribute to libido in ways that exogenous testosterone doesn't fully replicate. Estrogen production within the testes is also part of the picture. Some men, however, report the opposite: HCG raises estradiol levels enough to produce estrogen-dominant symptoms — water retention, emotional variability, reduced libido — and they reduce or discontinue it as a result. These opposing reports appear in the same threads, and the experienced voices in these communities usually note that individual response to HCG varies considerably and that estrogen management becomes a more active conversation when HCG is in the protocol.

Fertility is where the stakes rise. Men who want to remain on TRT but maintain the possibility of conception make up a significant portion of the HCG discussion. The reports on sperm count recovery with HCG-included TRT are cautiously positive — many men describe maintaining measurable sperm counts while on TRT plus HCG, and some describe successful conception. The caveat that appears consistently is this: HCG alone drives Leydig cell function and intratesticular testosterone, but FSH — follicle-stimulating hormone — is the signal that directly supports Sertoli cells and the spermatogenesis process itself. HCG does not replace FSH. For men whose fertility situation is more complex, or whose semen analysis after HCG is inadequate, the communities discuss the addition of hMG — human menopausal gonadotropin, which contains both LH and FSH activity — as a more complete approach to spermatogenesis support. This is a more expensive and logistically complex protocol, and it appears in these discussions as a step up from HCG rather than a first line, but it represents the fuller picture that the most fertility-focused participants eventually explore.

The through-line across all of these reports — testicular volume, libido, fertility, estrogen management — is that HCG is doing something mechanistically specific and that individual response varies widely. These accounts form a detailed, experience-based map of dosing patterns, timelines, and complications, but they carry a real positivity bias and no controls, which makes them context on the public conversation rather than a protocol. What HCG actually warrants — baseline labs, a defined fertility or atrophy goal, estradiol monitoring, and follow-up semen analysis where conception matters — is the kind of structure that only a qualified prescribing provider can put around it.